Viela Bio, a Gaithersburg, MD-based clinical-stage biotechnology company, completed a $75m in Series B funding.
The round, which brought the total capital raised since launch in February 2018 to more than $300m, was led by HBM Healthcare Investments, with participation from new investors Viking Global Investors, Cormorant Asset Management, Terra Magnum Capital Partners, Goldman Sachs, and Barer & Son Capital and existing investors Temasek.
Led by Bing Yao, Ph.D. Executive Chairman and Chief Executive Officer, Viela Bio is a clinical-stage biotechnology company advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease.
The company intends to use the funds to:
– support regulatory filing and pre-commercial planning for lead product candidate, inebilizumab, for the treatment of neuromyelitis optica spectrum disorder, or NMOSD, and
– advance development of additional clinical candidates targeting autoimmune and inflammatory diseases.